Clinical trial
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
NCT05228158 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- August 16, 2021
- Completion date
- March 31, 2028
- Enrollment
- 145 (estimated)
- Sites
- 135
Conditions
As the registry lists them; a condition with its own page is linked.